search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


An open, randomized, (out-patient-) clinical study into the effectiveness, durability and cost efficiency of Tiscover (cultured, autologous skin) for chronic leg wounds (ulcera cruris).


- candidate number1763
- NTR NumberNTR439
- ISRCTNISRCTN86386707
- Date ISRCTN created27-jan-2006
- date ISRCTN requested18-nov-2005
- Date Registered NTR14-okt-2005
- Secondary IDsN/A 
- Public TitleAn open, randomized, (out-patient-) clinical study into the effectiveness, durability and cost efficiency of Tiscover (cultured, autologous skin) for chronic leg wounds (ulcera cruris).
- Scientific TitleAn open, randomized, (out-patient-) clinical study into the effectiveness, durability and cost efficiency of Tiscover (cultured, autologous skin) for chronic leg wounds (ulcera cruris).
- ACRONYMTISCOVER
- hypothesisWe hypothesize that ulcers treated with Tiscover will significantly decrease in size resulting in most cases in full healing, compared to the control group which is not treated with Tiscover.
- Healt Condition(s) or Problem(s) studiedUlcera cruris venosa, Ulcers, Ulcers of mixed origin
- Inclusion criteria1. Ulcus cruris venosum, ulcus cruris arterio(lo)scleroticum and ulcers of mixed origin;
2. Non-vital ulcers which exist for at least 5 months and which do not respond to adequate compression therapy and local wound treatment;
3. Ulcers between 5 and 100 square centimeters;
4. Signed informed consent;
5. Ankle / arm index >0.7.
- Exclusion criteria1. Diabetic foot ulcers;
2. Serious co-morbidity which decreases the life expectancy to less than 2 years;
3. Use of high doses of corticosteroids and/or cytostatic drugs (>20 mg/day);
4. Diagnosed Penicillin allergy;
5. Serious infection of the ulcer bed at time t=0;
6. Disturbances of psychiatric nature where the following of medical advice becomes a problem;
7. Declining clinical treatment and/or follow up visits.
- mec approval receivedyes
- multicenter trialyes
- randomisedyes
- masking/blindingNone
- controlActive
- groupParallel
- Type2 or more arms, randomized
- Studytypeintervention
- planned startdate 15-okt-2005
- planned closingdate15-okt-2007
- Target number of participants100
- InterventionsTwo out-patient groups:
Control group (n=30): 1 week prior wound bed preparation with acellular allodermis;
Test group (n=30):1 week prior wound bed preparation with acellular allodermis followed by removal of allodermis and application of Tiscover;

Two in-patient groups:
Control group (n=20): 5 day prior wound bed preparation with Vacume Assisted Closure therapy (VAC);
Test group (n=20):5 day prior wound bed preparation with VAC followed by application of Tiscover.

All patients receive compression therapy. All patients have a weekly followup for the duration of 24 weeks.
- Primary outcomeEffectiveness of treatment of therapy resistent, chronic ulcera cruris (>5 months open; >2 months with no sign of healing), with Tiscover.
- Secondary outcome1. Determine whether hospitalization and wound bed preparation have a beneficial effect;
2. Evaluate unforeseen toxicity due to Tiscover treatment;
3. Evaluate the durability of treatment with Tiscover;
4. Determine whether out-patient treatment with Tiscover is possible;
5. Compare the costs of Tiscover treatment with present costs for caring/treatment of inert ulcera cruris without Tiscover.
- TimepointsN/A
- Trial web siteN/A
- statusstopped: trial finished
- CONTACT FOR PUBLIC QUERIESDr. E.M. Boer, de
- CONTACT for SCIENTIFIC QUERIESDr. S. Gibbs
- Sponsor/Initiator VU University Medical Center, Department of Dermatology
- Funding
(Source(s) of Monetary or Material Support)
NWO-Biopartner First Stage Grant
- PublicationsN/A
- Brief summaryAn open, randomized, multicenter trial into the effectiveness of treatment of chronic wounds (ulcera cruris) with a new skin substitute. Tiscover is an autologous full-thickness skin substitute of 3 cm2. Recently 19 ulcers have been treated with Tiscover and in more than 60% of the cases complete closure occured within 8 weeks, without any side effects. In total, 100 patients with ulcera cruris venosa, ulcera cruris arterio(lo)scleroticum or mixed origin (>6 months open; > 2 months with no sign of healing; size 5-100 cm2) will be included. They will be divided into an in-patient (n=40)and an out-patient (n=60) group - each consisting of a test and a control group. In the in-patient and out-patient groups, the wounds will be prepared with Vacume Assisted Closure therapy or acellula allodermis respectively. In the test group, Tiscover will then be applied and all groups will receive continued compression therapy. The reduction in ulcer size will be measured. Statistical analysis: Two group continuity corrected c2 test with a 2 sided p-value of <0.050 being significant The study is for a duration of 24 weeks for each patient.
- Main changes (audit trail)
- RECORD14-okt-2005 - 5-aug-2010


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl